Thrombolytic therapy for ischemic stroke - A review. Part I - Intravenous thrombolysis

Critical Care Medicine

Volumn 29, Issue 9, 2001, Pages 1812-1818

  Schellinger, Peter D ^a   Fiebach, Jochen B ^a   Mohr, Alexander ^a   Ringleb, Peter A ^a   Jansen, Olav ^b   Hacke, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Computed tomography; Diagnostic imaging; Diffusion magnetic resonance imaging; Intra arterial lysis; Intravenous lysis; Ischemic stroke; Perfusion magnetic resonance imaging; Review; Thrombolysis; Vertebrobasilar stroke

Indexed keywords

ALTEPLASE; DUTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE; UROKINASE;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUING EDUCATION; COST CONTROL; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

EID: 0034855790     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200109000-00027     Document Type: Review

References (47)

1. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and Other Cerebrovascular Disorders
2. Critical management of the acute stroke: Medical and surgical therapy
3. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
4. Thresholds in cerebral ischemia - The ischemic penumbra
5. Critical care of acute ischemic stroke
6. Update on thrombolytic therapy in ischemic stroke
7. Tissue plasminogen activator for acute ischemic stroke
8. Multi-center trial of hemodilution in ischemic stroke
9. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study
10. The fibrinolytic activity of hemolytic streptococci
11. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition
12. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro
13. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator
14. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
15. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA
16. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility
17. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke
18. Therapeutic thrombolysis in cerebral thromboembolism
19. Clinical evaluation for efficacy of tissue cultured urokinase (TCUK) on cerebral thrombosis by means of multi-centre double blind study
20. Clinical utility of urokinase in the treatment of acute stage cerebral thrombosis: Multi-center double blind study in comparison with placebo
21. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Multi-center double blind study in comparison with placebo
22. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke
23. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
24. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke
25. Cerebral vascular accidents in people over the age of 60: Prognosis
26. Functional evaluation: The Barthel Index
27. A pilot study of streptokinase for acute cerebral infarction
28. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
29. Termination of trial of streptokinase in severe acute ischemic stroke
30. Dissent: An alternative interpretation of MAST-I Multicentre
31. Thrombolytic therapy with streptokinase in acute ischemic stroke
32. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
33. Streptokinase in acute ischemic stroke: An individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project
34. Thrombolysis for acute ischaemic stroke
35. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
36. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
37. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk
38. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke
39. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
40. Effect of training in reading CT scans on patient selection for ECASS II
41. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification
42. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study
43. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
44. Trials of thrombolysis in acute ischemic stroke: Does the choice of primary outcome measure really matter?
45. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
46. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
47. Recommendations for stroke management